Skip to main content
Premium Trial:

Request an Annual Quote

Marina Aims for Industry Partnership in 2012, Posts Lower Q3 Losses


Marina Biotech said this week that it expects to forge at least one industry partnership in 2012, buoyed by positive preclinical data on its various oligonucleotide drug-discovery platforms.

Marina also released this week its third-quarter financial results, posting a sharp drop in losses amid reduced costs.

Earlier this month, the company announced that incorporating its unlocked nucleobase analogs into siRNAs could reduce microRNA-like off-target activity (GSN 11/3/2011).

Earlier in the year, the firm released data indicating that its conformationally restricted nucleotide technology could be used to develop effective miRNA antagonists (GSN 10/20/2011 &7/14/2011).

And in April, Marina published a paper showing that its DiLA2 liposomes can systemically deliver siRNAs against targets in the liver in animal models (GSN 4/28/2011).

Marina's “drug-discovery engine allows us to capitalize on the advantages of modulating mRNA and microRNA targets with single- or double-stranded constructs, as well as delivery options ranging from simple saline to liposomal and bacterial-based delivery systems,” Marina President and CEO Michael French said in a statement.

“We now believe we are one of the strongest potential partners for pharma companies in the sector and expect to be able to establish one or more partnerships in the coming year,” he added.

In the third quarter, Marina's net loss fell to $4.4 million, or $0.05 per share, from a year-ago loss of $8.3 million, or $0.39 a share.

Revenues in the period slipped to $300,000 from $1.1 million, in part reflecting the sale of non-core assets last year.

Research and development costs dropped to $3 million from $7.5 million, while selling, general, and administrative spending was down more than 50 percent to $1.9 million. In the third quarter last year, Marina recorded a number of charges related to its acquisition of Cequent Pharmaceuticals.

At the end of September, Marina had cash totaling $2.2 million.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.